Metagenomi Therapeutics (MGX) Receivables - Accured (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Receivables - Accured of $1.0 million for Q1 2026, down 37.5% year-over-year from $1.6 million in Q1 2025, and down 16.67% quarter-over-quarter from $1.2 million in Q4 2025.
Metagenomi Therapeutics (MGX) Receivables - Accured (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Receivables - Accured for 4 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Accured fell 37.5% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 37.5% YoY), while the FY2025 annual figure was $1.2 million, down 25.0% from the prior year.
- Receivables - Accured retreated to $1.0 million in Q1 2026 per MGX's latest filing, from $1.2 million in the prior quarter.
- Across five years, Receivables - Accured topped out at $1.6 million in Q3 2024 and bottomed at $1.0 million in Q4 2023.
- Historically, Receivables - Accured has averaged $1.3 million across 4 years, with a median of $1.3 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables - Accured jumped 60.0% — and 2026, when it slumped 37.5%.
- Metagenomi Therapeutics' Receivables - Accured stood at $1.0 million in 2023, then soared by 60.0% to $1.6 million in 2024, then retreated by 25.0% to $1.2 million in 2025, then fell by 16.67% to $1.0 million in 2026.
- Business Quant data shows MGX's Receivables - Accured at $1.0 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 900,000.00 |
| Jun 30, 2026 | 900,000.00 |
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |